


## Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma: Erratum

In the article, "Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma",<sup>[1]</sup> which appears in Volume 98, Issue 2 of *Medicine*, Figure 1 has been replaced with the below figure.



## Reference

 Peng J-H, Zhang X, Song J-L. Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma. *Medicine*. 98:2;e 13554.

Received: 12 January 2022 / Accepted: 12 January 2022 http://dx.doi.org/10.1097/MD.00000000028714

Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Peng J-H, Zhang X, Song J-L. Neoadjuvant chemotherapy reduces the expression rates of ER, PR, HER2, Ki67, and P53 of invasive ductal carcinoma. Medicine 2022;101:4(e28714).